Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 9/20 | 0.60 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.47 |
| ▸ | F10 | P00742 | 2/20 | 0.47 |
| ▸ | PLAU | P00749 | 2/20 | 0.47 |
| ▸ | PLAT | P00750 | 2/20 | 0.47 |
| ▸ | PRKCG | P05129 | 2/20 | 0.47 |
| ▸ | PRKCB | P05771 | 2/20 | 0.47 |
| ▸ | F7 | P08709 | 2/20 | 0.47 |
| ▸ | PRKCA | P17252 | 2/20 | 0.47 |
| ▸ | PRKCH | P24723 | 2/20 | 0.47 |
| ▸ | PRKCI | P41743 | 2/20 | 0.47 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.47 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.47 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.47 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.47 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.46 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5860115 | 0.89 | F2 (0.57) | F2PRSS1TPSAB1 | |
| SCHEMBL5860178 | 0.89 | F2 (0.59) | F2PRSS1TPSAB1 | |
| SCHEMBL514966 | 0.88 | F2 (0.59) | F2PRKD3F10PLAUPLAT | |
| SCHEMBL30171117 | 0.88 | F2 (0.76) | F2PRKD3F10PLAUPLAT | |
| SCHEMBL5862727 | 0.86 | F2 (0.57) | F2PRSS1TPSAB1 | |
| SCHEMBL5861466 | 0.86 | F2 (0.55) | F2PRKD3F10PLAUPLAT | |
| SCHEMBL5862699 | 0.85 | F2 (0.52) | F2PRKD3F10PLAUPLAT | |
| SCHEMBL5862711 | 0.84 | F2 (0.56) | F2PRSS1TPSAB1 | |
| SCHEMBL8939669 | 0.84 | F2 (0.54) | F2PRKD3F10PLAUPLAT | |
| SCHEMBL7205443 | 0.82 | F2 (0.49) | F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4401441-B2 | — | — | 2010-01-20 | — | — | JP | claimed |
| JP-2001502360-A | — | — | 2001-02-20 | — | — | JP | claimed |
| EP-0948308-A1 | METHODS FOR TREATING SKIN PIGMENTATION | JOHNSON & JOHNSON CONSUMER PRODUCTS, INC. (US) | 1999-10-13 | — | — | EP | claimed |
| WO-1999004752-A9 | METHODS FOR TREATING SKIN PIGMENTATION | JOHNSON & JOHNSON CONSUMER (US) | 1999-04-08 | — | — | WO | claimed |
| WO-1999004752-A2 | METHODS FOR TREATING SKIN PIGMENTATION | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 1999-02-04 | — | — | WO | claimed |
| US-20120027706-A1 | METHODS FOR TREATING SKIN PIGMENTATION | SHAPIRO STANLEY S (US) | 2012-02-02 | — | — | US | disclosed |
| US-8039026-B1 | Methods for treating skin pigmentation | JOHNSON & JOHNSON CONSUMER COMPANIES, INC (US) | 2011-10-18 | — | — | US | disclosed |
| US-20080249029-A1 | Administering (S)-N-Methyl-D-phenylalanyl-N-[4-[(aminoiminomethyl)aminol-1-(2-benzothiazolylcarbonyl)butyl-L-prolinamide as a protease activated receptor-2 modulator | SHAPIRO STANLEY S | 2008-10-09 | — | — | US | disclosed |
| EP-1037653-B1 | COMPOSITIONS AND METHODS FOR REGULATING PHAGOCYTOSIS AND ICAM-1 EXPRESSION | JOHNSON & JOHNSON CONSUMER (US) | 2006-09-06 | — | — | EP | disclosed |
| US-6750229-B2 | ADMINISTERING TO A MAMMAL A PIGMENTATION-CHANGING EFFECTIVE AMOUNT OF A BOWMAN-BIRK INHIBITOR OR OF NATURAL EXTRACT CONTAINING A BOWMAN-BIRK INHIBITOR | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2004-06-15 | — | — | US | disclosed |
| EP-0948308-B1 | METHODS FOR TREATING SKIN PIGMENTATION | JOHNSON & JOHNSON CONSUMER (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20020197244-A1 | Compositions and methods for regulating phagocytosis and ICAM-1 expression | SEIBERG MIRI (US) | 2002-12-26 | — | — | US | disclosed |
| US-6323219-B1 | PRODRUGS AND PEPTIDES FOR ANTIINFLAMMATORY AGENTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2001-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120027706-A1 | METHODS FOR TREATING SKIN PIGMENTATION | TYR, MC1R, NQO1 | F2 1151/4885PRKD3 334/4885F10 2783/4885 |
| US-20080249029-A1 | Administering (S)-N-Methyl-D-phenylalanyl-N-[4-[(aminoiminomethyl)aminol-1-(2-benzothiazolylcarbonyl)butyl-L-prolinamide as a protease activated receptor-2 modulator | MC1R, F2RL1, F2R | F2 914/4885PRKD3 1630/4885F10 2445/4885 |
| US-20020197244-A1 | Compositions and methods for regulating phagocytosis and ICAM-1 expression | ICAM1, CD47, VCAM1 | F2 2338/4885PRKD3 2914/4885F10 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.